$ 7,529

$ 8,538

$ 60,000

$ 20,000

$ 225,000

$ 5,000

$ 4,000

38,500

$ 6,600

$ 226,000

Development Liability - Additional Information (Detail) $ in Thousands				1 Months Ended				3 Months Ended
	Jan. 28, 2022 USD ($) Installment	Jan. 29, 2020 USD ($)	Feb. 28, 2019 USD ($) Installment	Dec. 31, 2022 USD ($)	May 31, 2022 USD ($)	Jan. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Jun. 07, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Interest expense								$ 7,529	$ 8,538
SFJ Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from SFJ agreement		$ 140,000	$ 60,000
Additional funding amount upon achievement of development milestones			$ 60,000
Number of milestone payments \| Installment			3
Increase in additional funding for development costs										$ 20,000
Obligated to pay initial payment	$ 5,000							421,500
Aggregate amount of additional annual payments	$ 225,000
Number of additional annual payments \| Installment	6
Payment made under agreement						$ 5,000	$ 4,000	38,500
First annual payment under agreement				$ 18,000	$ 11,500
Interest expense								$ 6,600
SFJ Agreement [Member] \| Regulatory Approval Granted US Food and Drug Administration [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Obligated to pay initial payment			$ 4,000
Aggregate amount of additional annual payments			$ 226,000
Number of additional annual payments \| Installment			6